Vancouver, BC - November 19, 2013 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the appointment of Rene David as its Chief Financial Officer and Chief Operating Officer.
Mr. David has over 20 years of experience in real estate development, finance, and business strategy. He started his career at VanCity, Canada's largest Credit Union as a real estate developer and then went into investment banking in Western Canada. He later expanded his interests to include the resource, and food and water industries, assisting corporations who are dealing with the globalization of local sources. In his normal course of duties, Mr. David's responsibilities include internal financial controls and analysis, procurement and contracts management. His continuous review of operating and capital plans is geared towards improving the internal controls and financial best practices in order to deliver highest value product and strong company values.
Mr. David holds a Bachelor's of Commerce Degree in Finance and Diploma in Urban Land Economics from the University of British Columbia. While there he was a member of the UBC Men's Jr. Varsity Volleyball Team [although golf is his current passion]. He is the founding member of BLU Gold and Crimson Opportunities and was recognized in Business in Vancouver's "Top 40 Under 40", a regional recognition of exemplary individuals in business. He also holds directorships in several other publicly traded companies including a Vancouver-based, mineral exploration company primarily focused on the discovery of viable molybdenum deposits.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We were very selective in our search for an operations person who also had skills in finance. With Rene joining the Abattis team we have better financial controls and increased knowledge in structured funding to ensure value in transactions as we move forward. I am pleased to have Rene join our team and welcome him to be a key part of the growth we have planned."
When asked to comment on his new appointment Mr. David replied, "I'm excited to join Abattis, Canada's first public company in the medical marihuana application process to become a licensed producer. I look forward to helping Abattis become a leader in this emerging industry in Canada. As the industry risk profile decreases through credibility and awareness of the true medicinal properties and health benefits of marihuana, we strive to offer a vehicle for the best quality product, customer experience as well as a conduit to investment in one of the fastest growing industries in North America."
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal marijuana in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical growing systems, extraction equipment/technology, and strategic marketing support to licensed growers and dispensaries. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. For more information, visit the Company's website at www.abattis.com.
ON BEHALF OF THE BOARD
"Mike Withrow"
Michael Withrow, President & CEO
Neither the CNSX Exchange nor its regulations services accepts responsibility
for the adequacy or accuracy of this release.